Matches in Wikidata for { <http://www.wikidata.org/entity/Q91482232> ?p ?o ?g. }
Showing items 1 to 47 of
47
with 100 items per page.
- Q91482232 description "artículu científicu espublizáu en payares de 2019" @default.
- Q91482232 description "scientific article published on 26 November 2019" @default.
- Q91482232 description "wetenschappelijk artikel" @default.
- Q91482232 description "наукова стаття, опублікована 26 листопада 2019" @default.
- Q91482232 name "Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease" @default.
- Q91482232 name "Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease" @default.
- Q91482232 type Item @default.
- Q91482232 label "Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease" @default.
- Q91482232 label "Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease" @default.
- Q91482232 prefLabel "Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease" @default.
- Q91482232 prefLabel "Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease" @default.
- Q91482232 P1433 Q91482232-2DBA5D2B-AAA3-4438-A512-02435290F30E @default.
- Q91482232 P1476 Q91482232-F5E1D45C-BD04-447D-B7F6-7B8BEB5A9218 @default.
- Q91482232 P2093 Q91482232-2663FA4D-A467-47EA-9EC9-BA2621CF8318 @default.
- Q91482232 P2093 Q91482232-29B1E1D0-6652-4144-AC4B-2B5479C4C076 @default.
- Q91482232 P2093 Q91482232-2D875B91-E2BB-438B-9099-F744341E0FE7 @default.
- Q91482232 P2093 Q91482232-74F0E3CD-2CF7-48A2-9421-833E84D73217 @default.
- Q91482232 P2093 Q91482232-7DB7CCDC-4A28-4D0E-BD36-1932BE212724 @default.
- Q91482232 P2093 Q91482232-8AC8C39E-4408-45DF-B093-43C10216973F @default.
- Q91482232 P2093 Q91482232-8E974E3A-0B08-43C3-9C47-F6FACEA7F616 @default.
- Q91482232 P2093 Q91482232-D22271A2-4FE5-4BD6-99F5-737EF0818C96 @default.
- Q91482232 P2093 Q91482232-EED36303-56B0-478F-95AC-8BC69D6BBC0A @default.
- Q91482232 P31 Q91482232-6135767A-C7DA-46F4-A20D-E25C91EC4275 @default.
- Q91482232 P356 Q91482232-6E0E5322-9988-42D2-955D-FD51ACB28362 @default.
- Q91482232 P50 Q91482232-77E3299C-8056-4EB9-AFD1-78CFD411BE7C @default.
- Q91482232 P577 Q91482232-30B839D3-06B2-41FC-BE08-81F8064E3B62 @default.
- Q91482232 P698 Q91482232-A9736F9F-4882-416B-8BC2-6790E3888E19 @default.
- Q91482232 P921 Q91482232-14F214C1-CCB5-4DF4-84A4-BCB7D9E6B5A0 @default.
- Q91482232 P356 BJD.18739 @default.
- Q91482232 P698 31773720 @default.
- Q91482232 P1433 Q4970191 @default.
- Q91482232 P1476 "Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease" @default.
- Q91482232 P2093 "A Gesierich" @default.
- Q91482232 P2093 "E Geissinger" @default.
- Q91482232 P2093 "F Schneider" @default.
- Q91482232 P2093 "H Kneitz" @default.
- Q91482232 P2093 "J F Lock" @default.
- Q91482232 P2093 "J Weber" @default.
- Q91482232 P2093 "L Haug" @default.
- Q91482232 P2093 "M Goebeler" @default.
- Q91482232 P2093 "V Glutsch" @default.
- Q91482232 P31 Q13442814 @default.
- Q91482232 P356 "10.1111/BJD.18739" @default.
- Q91482232 P50 Q60161428 @default.
- Q91482232 P577 "2019-11-26T00:00:00Z" @default.
- Q91482232 P698 "31773720" @default.
- Q91482232 P921 Q1427096 @default.